What is Bio-Rad Laboratories, Inc.'s earnings per share (EPS)?

Bio-Rad Laboratories, Inc. (BIO) reported diluted earnings per share of $27.85 for fiscal year 2025. This represents a 142.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bio-Rad Laboratories, Inc. (BIO) Financials

BIO

Trailing 12 months to June 30, 2026

Revenue $2.6B +1.4% YoY

Net Income $222.4M -30.3% YoY

EPS (Diluted) $7.99 -31.9% YoY

Free Cash Flow $353.1M -4.8% YoY

Market Cap $10.2B as of Oct 6, 2026

Price / Sales 3.9x on $2.6B revenue, trailing 12 months to June 30, 2026

Price / Earnings 45.7x on $222.4M net income, trailing 12 months to June 30, 2026

Price / Book 1.4x on $7.2B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIO SEC filings page.

Bio-Rad Laboratories, Inc. (BIO) reported $2.6B in revenue over the twelve months to Jun 30, 2026, up 1.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BIO FY2025 2026-10-03

Bio-Rad’s cash generation remains dependable, but FY2025’s earnings rebound came mostly outside the operating engine, not from stronger core profitability.

FY2025 net income reached $759.9M while operating income was only $47.2M, so the reported profit recovery was not matched by the core business. With operating margin at 1.8% and gross margin at 51.9%, the earnings gap points to items below operating income rather than improved operating performance.

Cash quality is better than the income statement suggests: FY2025 operating cash flow rose to $532.2M from $455.2M in FY2024, while free cash flow reached $374.6M. That conversion, despite weak operating profit, indicates reported cash generation is being supported by non-earnings factors such as noncash charges or working-capital movements.

The balance sheet is conservatively financed: FY2025’s current ratio was 5.6x and debt-to-equity was 0.2x, even after total liabilities increased to $3.1B. However, capital intensity is persistent: capital expenditures were $157.6M, consuming roughly two-thirds of operating cash flow and leaving reinvestment as a recurring claim on internally generated cash.

Financial Health Signals

Financial Health Score 52/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Bio-Rad Laboratories, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Bio-Rad Laboratories, Inc. has an operating margin of 1.8%, meaning the company retains $2 of operating profit per $100 of revenue. This results in a moderate score of 56/100, indicating healthy but not exceptional operating efficiency. This is down from 10.5% the prior year.

Growth

Bio-Rad Laboratories, Inc.'s revenue grew a modest 0.7% year-over-year to $2.6B. This slow but positive growth earns a score of 25/100.

Leverage

Bio-Rad Laboratories, Inc. has elevated debt relative to equity (D/E of 0.16), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 20/100, reflecting increased financial risk.

Liquidity

With a current ratio of 5.62, Bio-Rad Laboratories, Inc. holds $5.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 93/100.

Cash Flow

Bio-Rad Laboratories, Inc. converts 14.5% of revenue into free cash flow ($374.6M). This strong cash generation earns a score of 72/100.

Returns

Bio-Rad Laboratories, Inc.'s ROE of 10.2% shows moderate profitability relative to equity, earning a score of 44/100. This is up from -28.1% the prior year.

Altman Z-Score Safe

3.56

Bio-Rad Laboratories, Inc. scores 3.56, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($10.2B) relative to total liabilities ($3.1B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Bio-Rad Laboratories, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Mixed

0.70x

For every $1 of reported earnings, Bio-Rad Laboratories, Inc. generates $0.70 in operating cash flow ($532.2M OCF vs $759.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

0.96x

Bio-Rad Laboratories, Inc. earns $0.96 in operating income for every $1 of interest expense ($47.2M vs $49.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$651.0M

YoY-0.1%

QoQ+9.9%

5Y CAGR-1.9%

10Y CAGR+2.3%

Bio-Rad Laboratories, Inc. generated $651.0M in revenue in Q2 2026. This represents a decrease of 0.1% from the same quarter a year earlier. Against the prior quarter it is up 9.9%.

Net Income

$371.4M

YoY+16.9%

QoQ+170.5%

5Y CAGR-16.5%

10Y CAGR+36.4%

Bio-Rad Laboratories, Inc. reported $371.4M in net income in Q2 2026. This represents an increase of 16.9% from the same quarter a year earlier. Against the prior quarter it is up 170.5%.

EPS (Diluted)

$13.85

YoY+18.7%

QoQ+170.8%

5Y CAGR-14.6%

10Y CAGR+37.8%

Bio-Rad Laboratories, Inc. earned $13.85 per diluted share (EPS) in Q2 2026. This represents an increase of 18.7% from the same quarter a year earlier. Against the prior quarter it is up 170.8%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

$66.7M

YoY-5.8%

QoQ-14.6%

5Y CAGR-12.7%

10Y CAGR+3.9%

Bio-Rad Laboratories, Inc. generated $66.7M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 5.8% from the same quarter a year earlier. Against the prior quarter it is down 14.6%.

Cash & Debt

$517.0M

YoY+40.0%

QoQ+1.9%

5Y CAGR-6.7%

10Y CAGR+2.1%

Bio-Rad Laboratories, Inc. held $517.0M in cash against $803.0M in long-term debt as of Q2 2026.

Shares Outstanding

Diluted avg 27M

Bio-Rad Laboratories, Inc. had a weighted average of 27M diluted shares in Q2 2026; the shares outstanding count is not reported for that period.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

53.1%

YoY+0.1pp

QoQ+0.9pp

5Y change-2.9pp

10Y change-1.1pp

Bio-Rad Laboratories, Inc.'s gross margin was 53.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.

Operating Margin

11.2%

YoY-0.7pp

QoQ+5.4pp

Bio-Rad Laboratories, Inc.'s operating margin was 11.2% in Q2 2026, reflecting core business profitability. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.4 percentage points.

Net Margin

57.0%

YoY+8.3pp

QoQ+146.1pp

10Y change+53.8pp

Bio-Rad Laboratories, Inc.'s net profit margin was 57.0% in Q2 2026, showing the share of revenue converted to profit. This is up 8.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 146.1 percentage points.

Return on Equity

5.2%

YoY+0.7pp

QoQ+12.9pp

5Y change-2.7pp

10Y change+4.5pp

Bio-Rad Laboratories, Inc.'s ROE was 5.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.9 percentage points.

Capital Allocation

R&D Spending

$61.2M

YoY+1.2%

QoQ-2.7%

Bio-Rad Laboratories, Inc. invested $61.2M in research and development in Q2 2026. This represents an increase of 1.2% from the same quarter a year earlier. Against the prior quarter it is down 2.7%.

Share Buybacks

$31.5M

YoY-77.5%

QoQ-34.1%

Bio-Rad Laboratories, Inc. spent $31.5M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 77.5% from the same quarter a year earlier. Against the prior quarter it is down 34.1%.

Capital Expenditures

$32.0M

YoY-30.0%

QoQ+6.7%

5Y CAGR+6.5%

10Y CAGR+0.1%

Bio-Rad Laboratories, Inc. invested $32.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 30.0% from the same quarter a year earlier. Against the prior quarter it is up 6.7%.

BIO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIO quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$2.6B	$2.6B+0.7%	$2.6B-3.9%	$2.7B-4.7%	$2.8B-4.1%	$2.9B+14.8%	$2.5B+10.1%	$2.3B+1.0%	$2.3B+6.0%	$2.2B+4.4%	$2.1B+2.4%	$2.0B-7.2%	$2.2B+2.0%	$2.1B+3.1%	$2.1B-0.2%	$2.1B
Cost of Revenue	$1.2B	$1.2B+4.7%	$1.2B-4.6%	$1.2B+0.8%	$1.2B-3.9%	$1.3B+16.0%	$1.1B+5.0%	$1.1B-1.1%	$1.1B+9.6%	$972.5M+4.6%	$929.7M+3.6%	$897.8M-9.9%	$996.5M+4.4%	$954.2M+4.4%	$914.1M+2.2%	$894.7M
Gross Profit	$1.3B	$1.3B-2.8%	$1.4B-3.4%	$1.4B-9.0%	$1.6B-4.3%	$1.6B+13.9%	$1.4B+14.4%	$1.3B+2.8%	$1.2B+3.0%	$1.2B+4.3%	$1.1B+1.5%	$1.1B-4.8%	$1.2B0.0%	$1.2B+2.0%	$1.2B-2.0%	$1.2B
R&D Expenses	$265.7M	$275.6M-6.9%	$295.9M+19.6%	$247.4M-3.7%	$256.9M-1.4%	$260.6M+19.7%	$217.8M+7.4%	$202.7M+1.8%	$199.2M-20.4%	$250.2M+21.6%	$205.7M+6.6%	$193.0M-12.4%	$220.3M+4.4%	$211.0M+0.8%	$209.2M+17.8%	$177.6M
SG&A Expenses	$852.2M	$844.3M+3.7%	$814.0M-3.3%	$841.7M+1.7%	$827.8M-5.6%	$877.1M+9.8%	$798.8M-3.1%	$824.6M-1.2%	$834.8M+3.5%	$806.8M-1.0%	$814.7M+6.9%	$762.0M-5.7%	$808.2M+1.3%	$798.1M+17.1%	$681.8M-2.0%	$696.0M
Operating Income	$53.1M	$47.2M-82.5%	$269.0M-20.4%	$337.8M-30.0%	$482.6M-3.5%	$500.3M+18.8%	$421.3M+83.5%	$229.7M+322.2%	-$103.3M-186.7%	$119.3M+114.0%	$55.7M-66.6%	$166.7M+11.2%	$150.0M-11.5%	$169.5M-35.9%	$264.2M-13.5%	$305.2M
EBITDA	N/A	$212.6M-49.5%	$420.6M-13.0%	$483.7M-22.0%	$619.9M-2.8%	$637.9M+13.9%	$559.9M+53.9%	$363.9M+946.8%	$34.8M-87.0%	$267.9M+34.9%	$198.6M-33.5%	$298.5M-0.5%	$299.9M-5.3%	$316.7M-19.7%	$394.6M-7.4%	$426.2M
Interest Expense	$48.8M	$49.0M+0.2%	$48.9M-1.0%	$49.4M+29.7%	$38.1M+2356.5%	$1.6M-92.9%	$21.9M-6.6%	$23.4M-2.3%	$24.0M+4.1%	$23.0M-1.6%	$23.4M+7.8%	$21.7M-2.0%	$22.1M-63.9%	$61.3M+19.9%	$51.1M-3.8%	$53.1M
Income Tax	$128.0M	$235.6M+147.3%	-$498.3M-134.2%	-$212.8M+80.2%	-$1.1B-190.1%	$1.2B+8.2%	$1.1B+119.7%	$502.4M+241.7%	$147.0M+701.6%	-$24.4M-257.1%	$15.6M-57.5%	$36.6M-14.3%	$42.7M+23.5%	$34.6M-46.3%	$64.4M-4.0%	$67.0M
Net Income	$222.4M	$759.9M+141.2%	-$1.8B-189.4%	-$637.3M+82.4%	-$3.6B-185.3%	$4.3B+11.5%	$3.8B+116.9%	$1.8B+381.0%	$365.6M+199.1%	$122.2M+370.2%	$26.0M-76.2%	$109.2M+23.0%	$88.8M+14.2%	$77.8M-53.0%	$165.5M-7.6%	$179.0M
EPS (Basic)	N/A	$27.87+142.6%	-$65.36-199.5%	-$21.82+82.1%	-$121.79-185.4%	$142.61+11.3%	$128.13+117.4%	$58.93+381.1%	$12.25+197.3%	$4.12+368.2%	$0.88-76.5%	$3.74+21.4%	$3.08+13.2%	$2.72-53.5%	$5.85-8.5%	$6.39
EPS (Diluted)	$7.99	$27.85+142.6%	-$65.36-199.5%	-$21.82+82.1%	-$121.79-186.5%	$140.83+11.4%	$126.47+117.0%	$58.27+381.6%	$12.10+197.3%	$4.07+362.5%	$0.88-76.3%	$3.71+21.6%	$3.05+13.4%	$2.69-53.5%	$5.78-8.1%	$6.29
Diluted Shares (Avg)	N/A	27M-3.3%	28M-3.4%	29M-1.9%	30M-1.4%	30M+0.2%	30M-0.1%	30M-0.1%	30M+0.6%	30M+1.3%	30M+0.8%	29M+0.9%	29M+0.8%	29M+0.9%	29M+0.6%	28M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$651.0M-0.1%	$592.1M+1.1%	$693.2M+3.9%	$653.0M+0.5%	$651.6M+2.1%	$585.4M-4.2%	$667.5M-2.0%	$649.7M+2.8%
Cost of Revenue	$305.2M-0.4%	$282.7M+1.2%	$348.0M	$309.6M+5.4%	$306.3M+8.1%	$279.4M-1.9%	N/A	$293.8M-0.9%
Gross Profit	$345.8M+0.1%	$309.4M+1.1%	$345.2M+0.9%	$343.4M-3.5%	$345.3M-2.8%	$306.0M-6.1%	$342.0M-6.6%	$355.9M+6.0%
R&D Expenses	$61.2M+1.2%	$62.9M-14.4%	$70.3M	$71.3M-21.6%	$60.5M+2.7%	$73.5M+10.7%	N/A	$91.0M+109.0%
SG&A Expenses	$212.0M+2.1%	$212.4M+1.7%	$221.0M	$206.8M+3.2%	$207.7M+6.7%	$208.8M-2.8%	N/A	$200.4M-0.4%
Operating Income	$72.6M-5.8%	$34.1M+43.9%	-$118.9M	$65.3M+1.2%	$77.1M-24.0%	$23.7M-46.9%	N/A	$64.5M-29.1%
Interest Expense	$12.1M-4.0%	$12.3M+2.5%	$12.1M	$12.3M+1.7%	$12.6M+2.4%	$12.0M-2.4%	N/A	$12.1M-2.4%
Income Tax	$170.7M+77.4%	-$162.7M-938.7%	$209.2M	-$89.2M-142.8%	$96.2M+115.5%	$19.4M-81.9%	N/A	$208.4M+575.6%
Net Income	$371.4M+16.9%	-$527.1M-923.6%	$720.0M+200.6%	-$341.9M-152.3%	$317.8M+114.7%	$64.0M-83.3%	-$715.8M-304.7%	$653.2M+514.5%
EPS (Basic)	$13.89+19.0%	-$19.55-953.7%	$26.41+203.3%	-$12.70-154.3%	$11.67+115.3%	$2.29-83.0%	-$25.57-310.5%	$23.37+540.3%
EPS (Diluted)	$13.85+18.7%	-$19.55-953.7%	$26.39+203.2%	-$12.70-154.4%	$11.67+115.3%	$2.29-83.0%	-$25.57-310.6%	$23.34+541.2%
Diluted Shares (Avg)	27M-1.5%	27M-3.6%	N/A	27M-3.8%	27M-4.1%	28M-2.0%	N/A	28M-4.2%

Not reported in any period shown, so not listed: EBITDA.

BIO Balance Sheet

BIO quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$10.6B+12.9%	$9.4B-23.9%	$12.3B-8.9%	$13.5B-24.1%	$17.8B+37.2%	$13.0B+62.0%	$8.0B+42.7%	$5.6B+31.3%	$4.3B+11.0%	$3.9B+3.8%	$3.7B+11.0%	$3.3B-1.4%	$3.4B-1.6%	$3.4B+11.2%	$3.1B
Current Assets	$2.9B-4.1%	$3.0B-0.6%	$3.0B-3.5%	$3.2B+58.7%	$2.0B-7.0%	$2.1B-1.8%	$2.2B+7.7%	$2.0B+2.4%	$2.0B+7.2%	$1.8B+3.8%	$1.8B+3.6%	$1.7B-2.3%	$1.8B-9.3%	$1.9B+7.7%	$1.8B
Cash & Equivalents	$529.8M+8.5%	$488.1M+20.9%	$403.8M-7.0%	$434.2M-7.8%	$470.8M-28.9%	$662.2M+0.2%	$660.7M+53.1%	$431.5M+12.4%	$383.8M-15.9%	$456.3M-0.3%	$457.5M+10.7%	$413.3M+24.6%	$331.6M-28.5%	$463.4M-19.3%	$574.2M
Short-Term Investments	$1.0B-14.1%	$1.2B-2.2%	$1.2B-11.3%	$1.4B+239.8%	$399.1M+21.3%	$328.9M-27.5%	$454.0M+9.8%	$413.3M+11.3%	$371.2M-3.1%	$383.2M+16.6%	$328.7M+15.6%	$284.4M+2.5%	$277.4M-39.4%	$457.7M+91.6%	$238.9M
Inventory	$740.7M-2.5%	$760.0M-2.6%	$780.5M+8.5%	$719.3M+25.7%	$572.2M-8.0%	$622.3M+12.3%	$554.0M-5.1%	$583.8M-1.8%	$594.8M+13.3%	$525.0M+7.1%	$490.2M+4.1%	$471.0M-8.8%	$516.2M+13.4%	$455.1M+5.0%	$433.5M
Accounts Receivable	$460.6M+1.8%	$452.5M-7.5%	$489.0M-1.1%	$494.6M+16.8%	$423.5M+1.0%	$419.4M+6.8%	$392.7M+0.1%	$392.4M-15.6%	$464.8M+24.8%	$372.3M-4.9%	$391.5M+3.7%	$377.6M-10.7%	$422.7M+6.0%	$398.7M0.0%	$398.7M
Long-Term Investments	$6.1B+26.1%	$4.8B-37.1%	$7.7B-12.8%	$8.8B-38.6%	$14.4B+50.5%	$9.6B+106.1%	$4.6B+74.7%	$2.7B+158.4%	$1.0B+23.7%	$830.8M+15.4%	$719.8M+84.9%	$389.3M+3.0%	$377.9M+28.7%	$293.6M	$0
Goodwill	$579.8M+41.2%	$410.5M-0.7%	$413.6M+1.7%	$406.5M+17.0%	$347.3M+19.0%	$291.9M+10.5%	$264.1M+20.2%	$219.8M-56.6%	$506.1M+6.1%	$477.1M-3.8%	$495.9M-0.9%	$500.4M-3.4%	$517.8M+4.5%	$495.4M+5.7%	$468.9M
Total Liabilities	$3.1B+11.7%	$2.8B-21.4%	$3.6B-8.5%	$3.9B-5.5%	$4.1B+33.0%	$3.1B+37.2%	$2.3B+41.7%	$1.6B+18.5%	$1.3B+5.6%	$1.3B+4.3%	$1.2B+5.5%	$1.2B-3.8%	$1.2B-15.8%	$1.4B+5.6%	$1.4B
Current Liabilities	$517.0M+10.5%	$467.8M-10.5%	$522.8M-8.1%	$568.7M-16.5%	$680.9M+7.8%	$631.5M-30.3%	$905.5M+100.9%	$450.8M-10.3%	$502.7M+6.7%	$471.3M+6.8%	$441.4M-1.2%	$446.8M-8.4%	$487.5M+3.2%	$472.4M+2.9%	$459.1M
Non-Current Liabilities	$2.6B+12.0%	$2.3B-23.3%	$3.0B-8.5%	$3.3B-3.4%	$3.4B+39.5%	$2.5B+82.5%	$1.3B+18.3%	$1.1B+35.7%	$840.1M+5.0%	$800.0M+2.8%	$777.9M+9.7%	$709.4M-0.7%	$714.6M-25.2%	$955.6M+7.0%	$893.3M
Long-Term Debt	$1.2B+0.1%	$1.2B+0.1%	$1.2B+0.1%	$1.2B+11291.5%	$10.5M-14.2%	$12.3M-9.7%	$13.6M-96.9%	$438.9M+1.0%	$434.6M+0.1%	$434.2M+0.1%	$433.9M-0.4%	$435.7M0.0%	$435.6M-40.5%	$732.4M+0.1%	$731.7M
Total Equity	$7.5B+13.5%	$6.6B-24.8%	$8.7B-9.1%	$9.6B-29.7%	$13.7B+38.4%	$9.9B+71.8%	$5.8B+43.2%	$4.0B+37.2%	$2.9B+13.6%	$2.6B+3.8%	$2.5B+13.8%	$2.2B-0.1%	$2.2B+8.5%	$2.0B+15.5%	$1.7B
Retained Earnings	$8.2B+10.2%	$7.4B-19.9%	$9.3B-6.4%	$9.9B-26.8%	$13.5B+45.9%	$9.3B+69.4%	$5.5B+47.0%	$3.7B+103.3%	$1.8B+0.1%	$1.8B+1.1%	$1.8B+6.7%	$1.7B+5.5%	$1.6B+5.1%	$1.5B+12.4%	$1.4B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$10.3B+0.4%	$9.8B+2.8%	$10.6B+12.9%	$9.7B-8.6%	$10.2B+5.4%	$9.5B-24.4%	$9.4B-23.9%	$10.6B-10.9%
Current Assets	$3.0B+7.4%	$2.9B-3.1%	$2.9B-4.1%	$2.8B-7.0%	$2.8B-8.0%	$3.0B-0.8%	$3.0B-0.6%	$3.1B-2.9%
Cash & Equivalents	$517.0M+40.0%	$507.2M-2.7%	$529.8M+8.5%	$395.8M-3.6%	$369.3M-9.2%	$521.4M+20.3%	$488.1M+20.9%	$410.4M-10.4%
Short-Term Investments	$1.1B+9.7%	$1.1B-7.2%	$1.0B-14.1%	$1.0B-15.6%	$1.0B-16.9%	$1.1B-6.1%	$1.2B-2.2%	$1.2B-6.8%
Inventory	$780.6M-2.3%	$770.5M-2.5%	$740.7M-2.5%	$783.2M-2.6%	$798.8M-0.6%	$790.1M+0.9%	$760.0M-2.6%	$804.3M+3.7%
Accounts Receivable	$441.8M-6.0%	$426.2M+0.4%	$460.6M+1.8%	$464.7M+0.6%	$469.9M+5.5%	$424.7M-4.5%	$452.5M-7.5%	$461.9M+1.0%
Long-Term Investments	$5.7B+2.6%	$5.3B+6.4%	$6.1B+26.1%	$5.1B-15.7%	$5.6B+9.4%	$5.0B-37.7%	$4.8B-37.1%	$6.0B-16.8%
Goodwill	$574.3M-1.3%	$577.1M+39.2%	$579.8M+41.2%	$578.7M+39.4%	$581.6M+41.1%	$414.6M+0.4%	$410.5M-0.7%	$415.1M+2.0%
Total Liabilities	$3.1B-0.2%	$2.9B+3.2%	$3.1B+11.7%	$3.0B-5.0%	$3.1B+6.0%	$2.8B-20.0%	$2.8B-21.4%	$3.1B-10.5%
Current Liabilities	$961.3M+75.1%	$917.0M+81.0%	$517.0M+10.5%	$522.3M+4.9%	$548.9M+12.7%	$506.6M+8.7%	$467.8M-10.5%	$497.9M-10.8%
Non-Current Liabilities	$2.1B-16.5%	$2.0B-13.6%	$2.6B+12.0%	$2.4B-6.9%	$2.5B+4.7%	$2.3B-24.3%	$2.3B-23.3%	$2.6B-10.4%
Long-Term Debt	$803.0M-33.1%	$802.9M-33.1%	$1.2B+0.1%	$1.2B+0.1%	$1.2B+0.1%	$1.2B+0.1%	$1.2B+0.1%	$1.2B+0.1%
Total Equity	$7.2B+0.6%	$6.9B+2.6%	$7.5B+13.5%	$6.7B-10.0%	$7.1B+5.2%	$6.7B-26.2%	$6.6B-24.8%	$7.5B-11.0%
Retained Earnings	$8.0B+2.9%	$7.6B+2.3%	$8.2B+10.2%	$7.5B-8.3%	$7.8B+4.3%	$7.5B-22.4%	$7.4B-19.9%	$8.1B-8.7%

BIO Cash Flow Statement

BIO quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$492.6M	$532.2M+16.9%	$455.2M+21.4%	$374.9M+92.8%	$194.4M-71.0%	$669.5M+14.4%	$585.0M+27.8%	$457.9M+60.4%	$285.5M+174.2%	$104.1M-51.8%	$216.1M+16.0%	$186.2M-31.9%	$273.3M+61.6%	$169.1M-36.5%	$266.5M+1.4%	$262.7M
Depreciation & Amortization	N/A	$165.4M+9.1%	$151.6M+3.9%	$145.9M+6.3%	$137.3M-0.2%	$137.6M-0.7%	$138.6M+3.3%	$134.2M-2.8%	$138.1M-7.1%	$148.7M+4.1%	$142.9M+8.4%	$131.8M-12.1%	$149.9M+1.8%	$147.2M+12.9%	$130.4M+7.8%	$121.0M
Stock-Based Compensation	N/A	$58.0M-6.9%	$62.3M+1.6%	$61.3M+0.7%	$60.9M+18.9%	$51.2M+23.1%	$41.6M+16.9%	$35.6M+28.1%	$27.8M+18.8%	$23.4M+18.8%	$19.7M+15.9%	$17.0M+14.1%	$14.9M+8.8%	$13.7M+3.8%	$13.2M+23.4%	$10.7M
Capital Expenditures	$139.5M	$157.6M-4.8%	$165.6M+5.7%	$156.7M+38.9%	$112.8M-15.7%	$133.7M+23.2%	$108.6M+10.2%	$98.5M-24.1%	$129.8M+16.6%	$111.3M-21.3%	$141.4M+26.3%	$112.0M-7.4%	$121.0M+13.4%	$106.7M-25.3%	$142.9M+38.9%	$102.9M
Free Cash Flow	$353.1M	$374.6M+29.4%	$289.6M+32.7%	$218.2M+167.4%	$81.6M-84.8%	$535.7M+12.4%	$476.4M+32.6%	$359.4M+130.9%	$155.7M+2263.6%	-$7.2M-109.6%	$74.6M+0.6%	$74.2M-51.3%	$152.3M+143.8%	$62.5M-49.5%	$123.6M-22.7%	$159.8M
Investing Cash Flow	-$237.1M	-$189.7M-18.4%	-$160.2M-893.1%	$20.2M+101.7%	-$1.2B-51.4%	-$797.4M-1040.8%	-$69.9M+66.5%	-$208.9M-11.7%	-$187.0M-6.5%	-$175.6M+17.9%	-$213.9M-28.2%	-$166.9M+12.4%	-$190.5M-20830.3%	$919K+100.2%	-$400.4M-3.6%	-$386.3M
Financing Cash Flow	-$120.8M	-$283.2M-29.4%	-$218.8M+48.6%	-$425.6M-143.7%	$973.6M+1856.5%	-$55.4M+89.4%	-$523.0M-2198.3%	-$22.8M+53.2%	-$48.7M-14375.7%	$341K-96.2%	$9.0M+5.1%	$8.6M-26.6%	$11.7M+103.8%	-$311.7M-2576.1%	$12.6M+105.9%	-$213.6M
Share Buybacks	$132.7M	$295.5M+45.1%	$203.6M-52.5%	$428.7M+98.7%	$215.7M+331.4%	$50.0M-50.0%	$100.0M+257.2%	$28.0M-42.8%	$48.9M+1575.1%	$2.9M	$0	$0	$0	$0-100.0%	$101K	$0

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$98.7M-15.3%	$108.1M-16.8%	$164.9M+32.8%	$120.9M-26.1%	$116.5M+19.4%	$129.9M+86.1%	$124.2M+53.3%	$163.6M+67.4%
Stock-Based Compensation	N/A	$15.0M-2.0%	N/A	N/A	N/A	$15.3M0.0%	N/A	N/A
Capital Expenditures	$32.0M-30.0%	$30.0M-12.8%	$45.8M+6.8%	$31.7M-21.1%	$45.7M+8.0%	$34.4M-14.4%	$42.9M+1.5%	$40.2M-8.8%
Free Cash Flow	$66.7M-5.8%	$78.1M-18.2%	$119.1M+46.5%	$89.2M-27.7%	$70.8M+28.0%	$95.5M+222.6%	$81.3M+109.9%	$123.4M+130.1%
Investing Cash Flow	-$66.7M+42.2%	-$93.2M-3313.8%	-$34.2M-12.1%	-$43.0M+22.8%	-$115.4M-273.5%	$2.9M+106.7%	-$30.5M-142.3%	-$55.7M-486.3%
Financing Cash Flow	-$27.6M+79.8%	-$44.0M+55.0%	$3.3M+112.6%	-$52.5M+45.3%	-$136.3M-41.1%	-$97.7M	-$26.2M+86.9%	-$96.0M-260.9%
Share Buybacks	$31.5M-77.5%	$47.8M-53.1%	$0	$53.4M-45.5%	$140.2M+38.8%	$101.9M+2068.1%	$0-100.0%	$97.9M+359.2%

Not reported in any period shown, so not listed: Depreciation & Amortization, Dividends Paid.

BIO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIO quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	51.9%-1.9pp	53.7%+0.3pp	53.4%-2.5pp	55.9%-0.1pp	56.0%-0.4pp	56.5%+2.1pp	54.4%+0.9pp	53.4%-1.5pp	55.0%-0.1pp	55.0%-0.5pp	55.5%+1.4pp	54.2%-1.1pp	55.3%-0.6pp	55.8%-1.0pp	56.9%
Operating Margin	1.8%-8.7pp	10.5%-2.2pp	12.7%-4.6pp	17.2%+0.1pp	17.1%+0.6pp	16.6%+6.6pp	9.9%+14.4pp	-4.5%-10.0pp	5.5%+2.8pp	2.7%-5.6pp	8.3%+1.4pp	6.9%-1.0pp	8.0%-4.8pp	12.8%-1.9pp	14.7%
Net Margin	29.4%+101.3pp	-71.9%-48.0pp	-23.9%	-129.4%	145.6%	149.8%	76.1%+60.1pp	16.0%+10.3pp	5.7%+4.4pp	1.3%-4.2pp	5.4%+1.3pp	4.1%+0.4pp	3.6%-4.4pp	8.0%-0.6pp	8.6%
Return on Equity	10.2%+38.3pp	-28.1%-20.8pp	-7.3%+30.4pp	-37.7%-68.8pp	31.1%-7.5pp	38.6%+8.0pp	30.6%+21.5pp	9.1%+4.9pp	4.2%+3.2pp	1.0%-3.4pp	4.4%+0.3pp	4.1%+0.5pp	3.6%-4.7pp	8.2%-2.0pp	10.3%
Return on Assets	7.2%+26.9pp	-19.7%-14.5pp	-5.2%+21.7pp	-26.9%-50.8pp	23.9%-5.5pp	29.4%+7.4pp	22.0%+15.4pp	6.5%+3.7pp	2.9%+2.2pp	0.7%-2.3pp	2.9%+0.3pp	2.7%+0.4pp	2.3%-2.5pp	4.8%-1.0pp	5.8%
Current Ratio	5.62-0.9x	6.48+0.6x	5.83+0.3x	5.55+2.6x	2.92-0.5x	3.39+1.0x	2.41-2.1x	4.49+0.6x	3.930.0x	3.91-0.1x	4.03+0.2x	3.84+0.2x	3.61-0.5x	4.10+0.2x	3.92
Debt-to-Equity	0.160.0x	0.180.0x	0.140.0x	0.12+0.1x	0.000.0x	0.000.0x	0.00-0.1x	0.110.0x	0.150.0x	0.170.0x	0.170.0x	0.200.0x	0.20-0.2x	0.36-0.1x	0.42
Asset Turnover	0.240.0x	0.27+0.1x	0.220.0x	0.210.0x	0.160.0x	0.20-0.1x	0.29-0.1x	0.41-0.1x	0.510.0x	0.540.0x	0.54-0.1x	0.650.0x	0.630.0x	0.60-0.1x	0.67
FCF Margin	14.5%+3.2pp	11.3%+3.1pp	8.2%+5.3pp	2.9%-15.4pp	18.3%-0.4pp	18.7%+3.2pp	15.6%+8.8pp	6.8%+7.1pp	-0.3%-3.9pp	3.6%-0.1pp	3.7%-3.3pp	7.0%+4.1pp	2.9%-3.0pp	6.0%-1.7pp	7.7%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	53.1%+0.1pp	52.3%0.0pp	49.8%-1.4pp	52.6%-2.2pp	53.0%-2.6pp	52.3%-1.1pp	51.2%-2.5pp	54.8%+1.7pp
Operating Margin	11.2%-0.7pp	5.8%+1.7pp	-17.2%	10.0%+0.1pp	11.8%-4.1pp	4.0%-3.2pp	N/A	9.9%-4.5pp
Net Margin	57.0%+8.3pp	-89.0%-99.9pp	103.9%	-52.4%	48.8%	10.9%-51.9pp	-107.2%	100.5%
Return on Equity	5.2%+0.7pp	-7.7%-8.6pp	9.7%+20.6pp	-5.1%-13.8pp	4.5%+36.4pp	1.0%-3.3pp	-10.9%-14.9pp	8.7%+7.5pp
Return on Assets	3.6%+0.5pp	-5.4%-6.0pp	6.8%+14.4pp	-3.5%-9.7pp	3.1%+25.5pp	0.7%-2.4pp	-7.6%-10.5pp	6.2%+5.3pp
Current Ratio	3.14-2.0x	3.21-2.8x	5.62-0.9x	5.44-0.7x	5.12-1.2x	5.99-0.6x	6.48+0.6x	6.14+0.5x
Debt-to-Equity	0.11-0.1x	0.12-0.1x	0.160.0x	0.180.0x	0.170.0x	0.180.0x	0.180.0x	0.160.0x
Asset Turnover	0.060.0x	0.060.0x	0.070.0x	0.070.0x	0.060.0x	0.060.0x	0.070.0x	0.060.0x
FCF Margin	10.3%-0.6pp	13.2%-3.1pp	17.2%+5.0pp	13.7%-5.3pp	10.9%+2.2pp	16.3%+11.5pp	12.2%+6.5pp	19.0%+10.5pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Bio-Rad Laboratories, Inc. BIO	FY2025	$2.6B	$759.9M	29.4%	$10.2B	52/100
GLOBUS MEDICAL INC GMED	FY2025	$2.9B	$537.9M	18.3%	$10.2B	77/100
Masimo Corporation MASI	FY2025	$1.5B	-$151.5M	-9.9%	$9.4B	66/100
Bruker Corporation BRKR	FY2025	$3.4B	-$8.3M	-0.2%	$9.6B	44/100
iRhythm Holdings, Inc. IRTC	FY2025	$747.1M	-$45.0M	-6.0%	$3.6B	43/100
Glaukos Corporation GKOS	FY2025	$507.4M	-$187.7M	-37.0%	$9.7B	51/100

Where Bio-Rad Laboratories, Inc. Ranks

Frequently Asked Questions

What is Bio-Rad Laboratories, Inc.'s annual revenue?

Bio-Rad Laboratories, Inc. (BIO) reported $2.6B in total revenue for fiscal year 2025. This represents a 0.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bio-Rad Laboratories, Inc.'s revenue growing?

Bio-Rad Laboratories, Inc. (BIO) revenue grew by 0.7% year-over-year, from $2.6B to $2.6B in fiscal year 2025.

Is Bio-Rad Laboratories, Inc. profitable?

Yes, Bio-Rad Laboratories, Inc. (BIO) reported a net income of $759.9M in fiscal year 2025, with a net profit margin of 29.4%.

What is Bio-Rad Laboratories, Inc.'s EBITDA?

Bio-Rad Laboratories, Inc. (BIO) had EBITDA of $212.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Bio-Rad Laboratories, Inc. have?

As of fiscal year 2025, Bio-Rad Laboratories, Inc. (BIO) had $529.8M in cash and equivalents against $1.2B in long-term debt.

What is Bio-Rad Laboratories, Inc.'s gross margin?

Bio-Rad Laboratories, Inc. (BIO) had a gross margin of 51.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bio-Rad Laboratories, Inc.'s operating margin?

Bio-Rad Laboratories, Inc. (BIO) had an operating margin of 1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bio-Rad Laboratories, Inc.'s net profit margin?

Bio-Rad Laboratories, Inc. (BIO) had a net profit margin of 29.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bio-Rad Laboratories, Inc.'s return on equity (ROE)?

Bio-Rad Laboratories, Inc. (BIO) has a return on equity of 10.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bio-Rad Laboratories, Inc.'s free cash flow?

Bio-Rad Laboratories, Inc. (BIO) generated $374.6M in free cash flow during fiscal year 2025. This represents a 29.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bio-Rad Laboratories, Inc.'s operating cash flow?

Bio-Rad Laboratories, Inc. (BIO) generated $532.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bio-Rad Laboratories, Inc.'s total assets?

Bio-Rad Laboratories, Inc. (BIO) had $10.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bio-Rad Laboratories, Inc.'s capital expenditures?

Bio-Rad Laboratories, Inc. (BIO) invested $157.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bio-Rad Laboratories, Inc. spend on research and development?

Bio-Rad Laboratories, Inc. (BIO) invested $275.6M in research and development during fiscal year 2025.

Does Bio-Rad Laboratories, Inc. buy back shares?

Yes, Bio-Rad Laboratories, Inc. (BIO) spent $295.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Bio-Rad Laboratories, Inc.'s current ratio?

Bio-Rad Laboratories, Inc. (BIO) had a current ratio of 5.62 as of fiscal year 2025, which is generally considered healthy.

What is Bio-Rad Laboratories, Inc.'s debt-to-equity ratio?

Bio-Rad Laboratories, Inc. (BIO) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bio-Rad Laboratories, Inc.'s return on assets (ROA)?

Bio-Rad Laboratories, Inc. (BIO) had a return on assets of 7.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bio-Rad Laboratories, Inc.'s P/E ratio?

Bio-Rad Laboratories, Inc. (BIO) trades at 45.7x earnings, its market capitalization divided by net income of $222.4M net income, trailing 12 months to June 30, 2026. The market capitalization is $10.2B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Bio-Rad Laboratories, Inc.'s price-to-sales ratio?

Bio-Rad Laboratories, Inc. (BIO) trades at 3.9x sales, its market capitalization divided by revenue of $2.6B revenue, trailing 12 months to June 30, 2026. The market capitalization is $10.2B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Bio-Rad Laboratories, Inc.'s Altman Z-Score?

Bio-Rad Laboratories, Inc. (BIO) has an Altman Z-Score of 3.56, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Bio-Rad Laboratories, Inc.'s Piotroski F-Score?

Bio-Rad Laboratories, Inc. (BIO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bio-Rad Laboratories, Inc.'s earnings high quality?

Bio-Rad Laboratories, Inc. (BIO) has an earnings quality ratio of 0.70x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bio-Rad Laboratories, Inc. cover its interest payments?

Bio-Rad Laboratories, Inc. (BIO) has an interest coverage ratio of 0.96x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Bio-Rad Laboratories, Inc.?

Bio-Rad Laboratories, Inc. (BIO) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.